Polymyxin B/Neomycin/Hydrocortisone Oph Susp Rx
Generic Name and Formulations:
Polymyxin B sulfate 10000 Units, neomycin 0.35% (as sulfate), hydrocortisone 1%; per mL; contains thimerosal.
Various generic manufacturers
Indications for Polymyxin B/Neomycin/Hydrocortisone Oph Susp:
Ocular inflammation associated with infection.
1–2 drops or small amount of oint every 3–4 hours (may use susp more often); max 20mL or 8g per therapeutic course.
Ocular fungal, viral or mycobacterial infections.
Corneal or scleral thinning. Glaucoma. Monitor IOP, for secondary infections, and avoid abrupt cessation in prolonged use. Pregnancy (Cat.C). Nursing mothers: not recommended.
Antibiotics + steroid.
Local irritation, sensitization, masks infection, delays healing; in prolonged use: increased IOP, cataracts, corneal perforation, optic nerve damage.
Formerly known under the brand name Cortisporin.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|